Navlimetostat (BMS-986504) with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007 (AACRPanCa 2026) - Oct 15, 2026 - Abstract #PR013; "Background:In the phase 1 CA240-0007 study, navlimetostat (MTA-cooperative PRMT5 inhibitor) was well tolerated and had antitumor activity in pts with MTAP-del advanced solid tumors, including PDAC. Navlimetostat monotherapy showed durable antitumor activity and was well tolerated in pts with heavily pretreated advanced PDAC. Initial data of navlimetostat + GEM + nab-P showed promising antitumor activity and manageable safety, supporting further evaluation of navlimetostat in pts with MTAP-del PDAC. Analysis of two additional escalating dose cohorts in CA240-0007 SS3 is ongoing and the phase 2/3 MountainTAP-30 study of navlimetostat + GEM + nab-P is currently enrolling.Encore presentation:These data were originally presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting."
Clinical • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • MTAP
|
|
Ben George; Konstantinos Leventakos; Meredith S. Pelster; Jordi Rodón; Kyriakos P. Papadopoulos; Alexander I. Spira; Kathryn C. Arbour; Cesar A. Perez; Hani M. Babiker; Pasi A. Jänne; Richard Zuniga; Scott Paulson; Tanios Bekaii-Saab; Sreenivasa Chandana; Mandana Kamgar; Lars D. Engstrom; Antonella Mazzei-Abba; Alicia Cheong; Hong Shi; Jason T. Henry
|